About us

AMR Bio is a clinical phase biotechnology company dedicated to infection prevention, advancing XF-73, a Phase 3-ready, first-in-class topical antimicrobial designed to prevent post-surgical infections.

The company’s lead product, XF-73 Nasal, has demonstrated strong clinical efficacy in a Phase 2b study and is advancing towards Phase 3 development for the prevention of Staphylococcus aureus infections in surgical settings. The unique attributes of this product mean it could become the market leader for pre-surgery decolonisation, where peak sales could reach $1 billion.

AMR Bio’s proprietary XF platform also supports dermal applications targeting severe wound and skin infections, representing a significant adjacent market opportunity exceeding $20 billion. XF-73 Dermal has been granted Qualified Infectious Disease Product (QIDP) designation by the US FDA for burn wound infections, supporting accelerated development and extended market exclusivity.

AMR Bio is focused on progressing XF-73 through late-stage development, building strong clinical data packages, and seeking partners for the final clinical studies and commercialisation.